...Novartis has announced an immediate reduction in the price of its anti-malarial medicine Coartem... By cutting the cost of each treatment by more than a third to an average $1 (SFr1.25), the company says it is trying to improve access to the therapy in low-income regions, particularly Africa... Daniel Vasella, chairman and CEO of Novartis [said]..."The compelling need for an inexpensive and highly effective malaria treatment, especially in low-income countries, prompted our decision to provide Coartem below our costs. I am very pleased that the WHO and other organisations such as Unicef and Médecins Sans Frontières can now become even more effective in rolling back malaria"...